GlassScriptPhysician profile
Kevin Kline
NPI 1134575699
$4,278.00
in general payments reported to CMS, 2019-2025
29 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $102 · 2021: $1,212 · 2022: $572 · 2023: $640 · 2024: $864 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256 · Education: $29.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.24 |
| Education | $29.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $1,211.50 | 2021 | |
| Abbvie INC. | $963.27 | 2020-2025 | |
| Janssen Biotech, INC. | $318.45 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $242.69 | 2022-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $233.01 | 2023-2025 | Voquezna |
| Cook Medical LLC | $200.00 | 2022 | |
| Genzyme Corporation | $144.65 | 2022-2024 | |
| Celgene Corporation | $133.03 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $113.18 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $98.04 | 2022-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.98 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $67.13 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $62.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.20 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $46.41 | 2022-2025 | Suflave, Sutab |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $44.74 | 2019 | |
| Madrigal Pharmaceuticals | $38.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $29.42 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $26.62 | 2023 | Idacio |
| Ironwood Pharmaceuticals, INC | $22.37 | 2023 | Linzess |
| Boston Scientific Corporation | $22.23 | 2022 | |
| Evoke Pharma, INC. | $21.69 | 2023 | Gimoti |
| Gilead Sciences, INC. | $20.20 | 2024 | |
| Ferring Pharmaceuticals INC. | $18.94 | 2023 | Rebyota |
| Azurity Pharmaceuticals, INC. | $16.32 | 2025 | Suflave |
| Intra-Sana Laboratories | $15.80 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ardelyx, INC. | $15.44 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $15.00 | 2025 | Zenpep |
| Celltrion USA INC. | $13.21 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.